PPA News

Posted by: Matthew Helms on Mar 6, 2019

Johannes N. van den Anker, MD, PhD has been named the 2019 recipient of the Sumner J. Yaffe Lifetime Achievement Award in Pediatric Pharmacology and Therapeutics. The Award recognizes significant and sustained contributions toward the improvement of children’s health through the expansion of the field of pediatric pharmacology and therapeutics.

Dr. van den Anker is the Vice Chair of Pediatrics for Experimental Therapeutics, Evan and Cindy Jones Endowed Chair in Pediatric Clinical Pharmacology, Chief of the Division of Clinical Pharmacology, Children’s National Medical Center, Washington, DC, and Professor of Pediatrics, Pharmacology, Physiology, Genomics and Precision Medicine at the George Washington University, Washington, DC. Dr. van den Anker is also the Eckenstein-Geigy Distinguished Professor and Head of the Paediatric Pharmacology and Pharmacometrics Research Group at the University Children’s Hospital in Basel, Switzerland. He has adjunct faculty appointments at The Johns Hopkins University School of Medicine in Baltimore, Maryland and Erasmus MC Sophia Children’s Hospital in Rotterdam, the Netherlands. He also serves part time as Chief Medical Officer at ReveraGen BioPharma, Inc.

He is a Fellow of the American Academy of Pediatrics and the American College of Clinical Pharmacology.

From 2016-2018 Dr. van den Anker served as the President of the American College of Clinical Pharmacology, where he also served as Secretary. He currently serves as the President of the European Society of Developmental, Perinatal, and Paediatric Pharmacology. Dr. van den Anker has received numerous awards form highly recognizable national and international organizations for the depth, breadth and extent of his clinical and research publications focused on the improvement of the care of ill neonates, infants and children. He has authored or co-authored over 426 peer-reviewed publications, 67 book chapters and over 50 “Letters” addressing contemporary issues important to pediatric clinical pharmacology. His authoritative counsel and recommendations are frequently sought and Dr. van den Anker has served on numerous international, professional, academic and national (e.g., NIH) Committees.